Janssen’s IMBRUVICA® receives recommendation to broaden treatment application for CLL patients
Janssen-Cilag International NV have reported that their therapy IMBRUVICA® (ibrutinib) has received a ‘Positive Opinion’ from the CHMP recommending that its use be extended for CLL patients.
Click on this link for more information.
